Current Position, Affiliation
- Professor of Trials and Epidemiology of Kidney Disease, co-lead Renal Studies Group, University of Oxford, UK
Education / Training
- 2003, MBBS, University College London
- 2013, M.D., University of Cambridge
Professional and Research Experience
- 2023, Professor of Trials and Epidemiology of Kidney Disease, University of Oxford
Awards & Honors
- 2023, Distinguished Fellow of the European Renal Association (FERA)
- 2020, Fellowship of the Royal College of Physicians of United Kingdom (FRCP)
Selected Publications
- The potential for improving cardio-renal outcomes in chronic kidney disease with the aldosterone synthase inhibitor vicadrostat (BI 690517): a rationale for the EASi-KIDNEY trial. Judge PK, Tuttle KR, Staplin N, Hauske SJ, Zhu D, Sardell R, Cronin L, Green JB, Agrawal N, Arimoto R, Mayne KJ, Sammons E, Brueckmann M, Shah SV, Rossing P, Nangaku M, Landray MJ, Wanner C, Baigent C, Haynes R, Herrington WG.Nephrol Dial Transplant. 2024 Nov 12:gfae263. doi: 10.1093/ndt/gfae263. Online ahead of print.
- Long-term effects of empagliflozin in chronic kidney disease. EMPA-KIDNEY Collaborative Group. NEJM 2024 (ePress 25Oct2024)
- Effects of Empagliflozin on Progression of Chronic Kidney Disease: A Pre-specified Secondary Analysis from the EMPA-KIDNEY trial. EMPA-KIDNEY Collaborative Group. Lancet Diabetes Endocrinology. 2024 Jan; 12(1):39-50.
- Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials. NDPH Renal Studies Group & SMART collaboration. Lancet 2022. Nov 19;400(10365):1788-1801.
- Empagliflozin in Patients with Chronic Kidney Disease. EMPA-KIDNEY collaborative group. New Engl J Med. 2023 Jan 12;388(2):117-127.
Keynote Speech
Role
Speaker
Date & Time
12/05 12:15 - 13:15
Place
Room 1 ( 701A )
Lecture Title
Vast Trials Saving Tiny Nephrons: Identifying Key Common Pathways to Kidney Failure